Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Med Phys. 2012 Jun;39(6):3476-83. doi: 10.1118/1.4719959.
Molecular breast imaging (MBI) has shown promise as an adjunct screening technique to mammography for women with dense breasts. The demonstration of reliable lesion detection with MBI performed at low administered doses of Tc-99 m sestamibi, comparable in effective radiation dose to screening mammography, is essential to adoption of MBI for screening. The concept of performing low-dose MBI with dual-head cadmium zinc telluride (CZT) gamma cameras has been investigated in phantoms in Part I. In this work, the objectives were to evaluate the impact of the count sensitivity improvement methods on image quality in patient MBI exams and to determine if adequate lesion detection could be achieved at reduced doses.
Following the implementation of two count sensitivity improvement methods, registered collimation optimized for near-field imaging and energy acceptance window optimized for CZT, MBI exams were performed in the course of clinical care. Clinical image count density (counts/cm(2)) was compared between standard MBI [740 MBq (20 mCi) Tc-99 m sestamibi, standard collimation, standard energy window] and low-dose MBI [296 MBq (8 mCi) Tc-99 m sestamibi, optimized collimation, wide energy window] in a cohort of 50 patients who had both types of MBI exams performed. Lesion detection at low doses was evaluated in a separate cohort of 32 patients, in which low-dose MBI was performed following 296 MBq injection and acquired in dynamic mode, allowing the generation of images acquired for 2.5, 5, 7.5, and 10 min/breast view with proportionately reduced count densities. Diagnostic accuracy at each count density level was compared and kappa statistic was used to assess intrareader agreement between 10 min acquisitions and those at shorter acquisition durations.
In patient studies, low-dose MBI performed with 296 MBq Tc-99 m sestamibi and new optimal collimation/wide energy window resulted in an average relative gain in count density of 4.2 ± 1.3 compared to standard MBI performed with 740 MBq. Interpretation of low-dose 296 MBq images with count densities corresponding to acquisitions of 2.5, 5, 7.5, and 10 min/view and median lesion size of 1.4 cm resulted in similar diagnostic accuracy across count densities and substantial to near-perfect intrareader agreement between full 10 min-views and lower count density views.
Review of patient studies showed that registered optimized collimation and wide energy window resulted in a substantial gain in count sensitivity as previously indicated by phantom results. This proof of concept work indicates that MBI performed at administered doses of 296 MBq Tc-99 m sestamibi with the applied count sensitivity improvements permits the detection of small breast lesions in patients. Findings suggest that further reductions in acquisition duration or administered dose may be achievable.
分子乳腺成像(MBI)已显示出作为致密乳腺女性乳房摄影术的辅助筛查技术的潜力。在低剂量 Tc-99m sestamibi 下进行的 MBI 可靠显示病变检测的证明,其有效辐射剂量与筛查乳房 X 光摄影术相当,对于 MBI 筛查的采用至关重要。在第一部分中,已经在体模中研究了使用双探头碲锌镉(CZT)伽马相机进行低剂量 MBI 的概念。在这项工作中,目的是评估计数灵敏度提高方法对患者 MBI 检查中图像质量的影响,并确定是否可以在降低剂量下实现足够的病变检测。
在实施两种计数灵敏度提高方法后,对近场成像进行了注册优化的准直和针对 CZT 的能量接受窗优化,然后在临床护理过程中进行 MBI 检查。在接受了两种类型的 MBI 检查的 50 名患者的队列中,比较了标准 MBI [740MBq(20mCi)Tc-99m sestamibi、标准准直器、标准能量窗]和低剂量 MBI [296MBq(8mCi)Tc-99m sestamibi、优化准直器、宽能量窗]的临床图像计数密度(每平方厘米计数)。在另外 32 名患者的队列中评估了低剂量的病变检测,其中在注射 296MBq 后进行了低剂量 MBI,并以动态模式采集,允许生成每乳房视图采集 2.5、5、7.5 和 10 分钟/视图的图像,相应的计数密度降低。比较了每个计数密度水平的诊断准确性,并使用kappa 统计量评估了 10 分钟采集与较短采集持续时间之间的读者内一致性。
在患者研究中,使用 296MBq Tc-99m sestamibi 进行低剂量 MBI 并采用新的优化准直器/宽能量窗,与使用 740MBq 进行标准 MBI 相比,平均计数密度提高了 4.2±1.3。对应于采集 2.5、5、7.5 和 10 分钟/视图的计数密度的低剂量 296MBq 图像的解释,以及中位病变大小为 1.4cm,在整个计数密度范围内具有相似的诊断准确性,并且在全 10 分钟视图和较低计数密度视图之间具有实质性到近乎完美的读者内一致性。
患者研究表明,注册优化准直器和宽能量窗在体模研究中表现出了计数灵敏度的显著提高,正如之前的体模研究结果所示。这项概念验证工作表明,在应用所提出的计数灵敏度提高的情况下,使用 296MBq Tc-99m sestamibi 进行 MBI 可以在患者中检测到小的乳腺病变。研究结果表明,可能进一步减少采集时间或给药剂量。